233 related articles for article (PubMed ID: 32758410)
1. Von Willebrand Factor Concentrate Administration for Acquired Von Willebrand Syndrome- Related Bleeding During Adult Extracorporeal Membrane Oxygenation.
Mazzeffi M; Bathula A; Tabatabai A; Menaker J; Kaczorowski D; Madathil R; Galvagno S; Pasrija C; Rector R; Tanaka K; Herr D
J Cardiothorac Vasc Anesth; 2021 Mar; 35(3):882-887. PubMed ID: 32758410
[TBL] [Abstract][Full Text] [Related]
2. In Vitro Comparison of Recombinant and Plasma-Derived von Willebrand Factor Concentrate for Treatment of Acquired von Willebrand Syndrome in Adult Extracorporeal Membrane Oxygenation Patients.
Mazzeffi M; Henderson R; Krause E; Rabin J; Madathil R; Chow J; Grazioli A; Meyer M; Wu Z; Tanaka K
Anesth Analg; 2022 Feb; 134(2):312-321. PubMed ID: 34903705
[TBL] [Abstract][Full Text] [Related]
3. Von Willebrand Factor-GP1bα Interactions in Venoarterial Extracorporeal Membrane Oxygenation Patients.
Mazzeffi M; Hasan S; Abuelkasem E; Meyer M; Deatrick K; Taylor B; Kon Z; Herr D; Tanaka K
J Cardiothorac Vasc Anesth; 2019 Aug; 33(8):2125-2132. PubMed ID: 30595484
[TBL] [Abstract][Full Text] [Related]
4. Acquired von Willebrand disease in children undergoing extracorporeal membrane oxygenation: a prospective observational study.
Drop JG; Wildschut ED; de Maat MPM; van Rosmalen J; de Boode WP; de Hoog M; Heleen van Ommen C
J Thromb Haemost; 2023 Dec; 21(12):3383-3392. PubMed ID: 37579879
[TBL] [Abstract][Full Text] [Related]
5. Changes in von Willebrand Factor Multimers, Concentration, and Function During Pediatric Extracorporeal Membrane Oxygenation.
Van Den Helm S; Letunica N; Barton R; Weaver A; Yaw HP; Karlaftis V; McCafferty C; Cai T; Newall F; Horton SB; Chiletti R; Johansen A; Best D; McKittrick J; Butt W; d'Udekem Y; MacLaren G; Linden MD; Ignjatovic V; Monagle P
Pediatr Crit Care Med; 2023 Apr; 24(4):268-276. PubMed ID: 36602314
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease.
Lillicrap D; Poon MC; Walker I; Xie F; Schwartz BA;
Thromb Haemost; 2002 Feb; 87(2):224-30. PubMed ID: 11858481
[TBL] [Abstract][Full Text] [Related]
7. Extracorporeal membrane oxygenation induces short-term loss of high-molecular-weight von Willebrand factor multimers.
Tauber H; Ott H; Streif W; Weigel G; Loacker L; Fritz J; Heinz A; Velik-Salchner C
Anesth Analg; 2015 Apr; 120(4):730-6. PubMed ID: 25565317
[TBL] [Abstract][Full Text] [Related]
8. von Willebrand factor/factor VIII concentrate (Humate-P) for management of elective surgery in adults and children with von Willebrand disease.
Gill JC; Shapiro A; Valentino LA; Bernstein J; Friedman C; Nichols WL; Manco-Johnson M
Haemophilia; 2011 Nov; 17(6):895-905. PubMed ID: 21535320
[TBL] [Abstract][Full Text] [Related]
9. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).
Michiels JJ; Berneman ZN; van der Planken M; Schroyens W; Budde U; van Vliet HH
Blood Coagul Fibrinolysis; 2004 Jun; 15(4):323-30. PubMed ID: 15166918
[TBL] [Abstract][Full Text] [Related]
10. Acquired von Willebrand syndrome in patients treated with veno-arterial extracorporeal membrane oxygenation.
Tamura T; Horiuchi H; Obayashi Y; Fuki M; Imanaka M; Kuroda M; Nishimura S; Amano M; Sakamoto J; Tamaki Y; Enomoto S; Miyake M; Kondo H; Izumi C; Nakagawa Y
Cardiovasc Interv Ther; 2019 Oct; 34(4):358-363. PubMed ID: 30656612
[TBL] [Abstract][Full Text] [Related]
11. Acquired von Willebrand syndrome in paediatric patients during mechanical circulatory support.
Kubicki R; Stiller B; Kroll J; Siepe M; Beyersdorf F; Benk C; Höhn R; Grohmann J; Fleck T; Zieger B
Eur J Cardiothorac Surg; 2019 Jun; 55(6):1194-1201. PubMed ID: 30590475
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate-P): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy.
Gill JC; Ewenstein BM; Thompson AR; Mueller-Velten G; Schwartz BA;
Haemophilia; 2003 Nov; 9(6):688-95. PubMed ID: 14750934
[TBL] [Abstract][Full Text] [Related]
13. Impact of extracorporeal membrane oxygenation treatments on acquired von Willebrand syndrome in patients with out-of-hospital cardiac arrest: a retrospective observational study.
Chiba Y; Goto K; Suzuki M; Horiuchi H; Hayakawa M
Thromb J; 2024 May; 22(1):46. PubMed ID: 38822325
[TBL] [Abstract][Full Text] [Related]
14. Acquired von Willebrand Syndrome and Desmopressin Resistance During Venovenous Extracorporeal Membrane Oxygenation in Patients With COVID-19: A Prospective Observational Study.
Kalbhenn J; Glonnegger H; Büchsel M; Priebe HJ; Zieger B
Crit Care Med; 2022 Aug; 50(8):1246-1255. PubMed ID: 35234414
[TBL] [Abstract][Full Text] [Related]
15. Acquired von Willebrand syndrome and impaired platelet function during venovenous extracorporeal membrane oxygenation: Rapid onset and fast recovery.
Kalbhenn J; Schlagenhauf A; Rosenfelder S; Schmutz A; Zieger B
J Heart Lung Transplant; 2018 Aug; 37(8):985-991. PubMed ID: 29650295
[TBL] [Abstract][Full Text] [Related]
16. Management of a COVID-19 Patient during ECMO: Paying Attention to Acquired von Willebrand Syndrome.
Hayakawa M; Takano K; Kayashima M; Kasahara K; Fukushima H; Matsumoto M
J Atheroscler Thromb; 2021 Apr; 28(4):396-401. PubMed ID: 33116032
[TBL] [Abstract][Full Text] [Related]
17. The pharmacokinetic diversity of two von Willebrand factor (VWF)/ factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Results from a prospective, randomised crossover study.
Kessler CM; Friedman K; Schwartz BA; Gill JC; Powell JS;
Thromb Haemost; 2011 Aug; 106(2):279-88. PubMed ID: 21725579
[TBL] [Abstract][Full Text] [Related]
18. Acquired von Willebrand syndrome in congenital heart disease surgery: results from an observational case-series.
Icheva V; Nowak-Machen M; Budde U; Jaschonek K; Neunhoeffer F; Kumpf M; Hofbeck M; Schlensak C; Wiegand G
J Thromb Haemost; 2018 Nov; 16(11):2150-2158. PubMed ID: 29908036
[TBL] [Abstract][Full Text] [Related]
19. Comparison of inhibitory and binding characteristics of an antibody causing acquired von Willebrand syndrome: an assay for von Willebrand factor binding by antibody.
Fricke WA; Brinkhous KM; Garris JB; Roberts HR
Blood; 1985 Sep; 66(3):562-9. PubMed ID: 3927998
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study.
Federici AB; Baudo F; Caracciolo C; Mancuso G; Mazzucconi MG; Musso R; Schinco PC; Targhetta R; Mannuccio Mannucci P
Haemophilia; 2002 Nov; 8(6):761-7. PubMed ID: 12410644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
